Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 420

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 420
---
if available, may involve restrictive covenants, and strategic relationships, if necessary, to raise additional funds, and may require
that we relinquish valuable rights.

23

Because
we have a limited operating history, you may not be able to accurately evaluate our operations.

We
have had limited operations to date. Therefore, we have a limited operating history upon which to evaluate the merits of investing in
our company. Our stockholders should be aware of the difficulties normally encountered by new companies and the high rate of failure
of such enterprises. The likelihood of success must be considered in light of the problems, expenses, difficulties, complications, and
delays encountered in connection with the operations that we plan to undertake. These potential problems include, but are not limited
to, unanticipated problems relating to the ability to generate sufficient cash flow to operate our business, and additional costs and
expenses that may exceed current estimates. We expect to continue to incur significant losses into the foreseeable future. We recognize
that if the effectiveness of our business plan is not forthcoming, we will not be able to continue business operations. There is no history
upon which to base any assumption as to the likelihood that we will prove successful, and it is doubtful that we will generate any operating
revenues or ever achieve profitable operations. If we are unsuccessful in addressing these risks, our business will most likely fail.

We
will need to raise additional financing for the continuation of our operations.

Because
we have generated no revenues and currently operate at a loss, we are completely dependent on the continued availability of financing
in order to continue our business operations. There can be no assurance that financing sufficient to enable us to continue our operations
will be available to us in the future.

We
will need additional funds to complete further development of our business plan to achieve a sustainable level where ongoing operations
can be funded out of revenues. We expect that adequate resources are available to fund our operations and initial clinical development
programs midway through the first quarter of 2026. We will require further funding to fully implement our business plan
to its fullest potential and achieve our growth plans. There is no assurance that any additional financing will be available or if available,
on terms that will be acceptable to us.

Our
failure to obtain future financing or to produce levels of revenue to meet our financial needs could result in our inability to continue
as a going concern and the failure of our business.

Our
operating results may fluctuate, which could have a negative impact on our ability to